SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories trades in green on launching Perampil tablets

11 Jun 2021 Evaluate

Alkem Laboratories is currently trading at Rs. 3143.60, up by 13.90 points or 0.44% from its previous closing of Rs. 3129.70 on the BSE.

The scrip opened at Rs. 3133.65 and has touched a high and low of Rs. 3149.50 and Rs. 3130.00 respectively. So far 909 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3223.65 on 09-Jun-2021 and a 52 week low of Rs. 2285.00 on 19-Jun-2020.

Last one week high and low of the scrip stood at Rs. 3223.65 and Rs. 3061.35 respectively. The current market cap of the company is Rs. 37420.26 crore.

The promoters holding in the company stood at 60.16%, while Institutions and Non-Institutions held 17.62% and 22.22% respectively.

Alkem Laboratories has launched Perampil (Perampanel) tablets 2 mg/4 mg/6 mg on June 9, 2021 to make the treatment accessible to patients and healthcare providers improving their quality of life. Alkem has launched Perampil, at 2 mg Rs 49 per strip of 7 tablets, 4 mg Rs 180 per strip of 15 tablets and 6 mg – Rs 300 per strip of 15 tablets, to improve patient access.

This product reaffirms Alkem’s commitment towards improving epilepsy care by bringing multiple treatment options of quality products to patients and health care professionals in India. Alkem had also launched Brivasure (Brivaracetam) tablets in March 2021 for the adjunctive management of partial onset seizure with or without secondary generalization.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.


Alkem Laboratories Share Price

5440.10 70.90 (1.32%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×